江蘇瑞科生物技術股份有限公司 Jiangsu Recbio Technology Co., Ltd. ( a joint stock company incorporated in the People's Republic of China with limited liability) Stock Code 股份代號 : 2179 （於中華人民共和國註冊成立的股份有限公司） ANNUAL REPORT 2024 年 報 Contents 目錄 | 2 | Corporate Information | 公司資料 | | --- | --- | --- | | 6 | Chairman's Statement | 主席致辭 | | 9 | Financial Highlights | 財務摘要 | | 10 | Management Discussion and Analysis | 管理層討論與分析 | | 40 | Biographies of Directors, Supervisors and | 董事、監事及高級管理層履歷 | | | Senior Management | | | 61 | Di ...

截至2024年12月31日止年度的全年業績公告 及 建議委任董事會觀察員 董事會欣然公佈本集團截至2024年12月31日止年度經審核簡明綜合業績，連同截 至2023年12月31日止年度之經審核比較數字。 業務摘要 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Jiangsu Recbio Technology Co., Ltd. 江蘇瑞科生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2179） 於報告期至本公告日期，我們快速推進產品研發，在研管線及業務運營方面達到 以下里程碑及進展： REC603－重組九價HPV疫苗 九價HPV疫苗可預防約90%的宮頸癌及90%的肛門及生殖器疣，被廣泛認為是針 對HPV的最有效疫苗。目前，尚無國產九價HPV疫苗獲批在中國銷售。 我們正在進行REC603中國III期臨床試驗，正在按照臨床方案開展定期隨訪工 作。我們已完成第36個月的訪視觀察，並已啟動第42個月的訪視觀察。我們將採 取病 ...

INTERIM REPORT 2024 中期報告 江蘇瑞科生物技術股份有限公司 Jiangsu Recbio Technology Co., Ltd. ( a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） Stock Code 股份代號：2179 Jiangsu Recbio Technology Co., Ltd. 江蘇瑞科生物技術股份有限公司 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-------|-------|----------------------------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------|-------| | | | | | | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Jiangsu Recbio Technology Co., Ltd. 江蘇瑞科生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2179） 截至2024年6月30日止六個月的未經審核中期業績公告 董事會欣然公佈本集團截至2024年6月30日止六個月的未經審核簡明綜合業績， 連同截至2023年6月30日止六個月未經審核的比較數字。 業務摘要 於報告期至本公告日期，我們快速推進產品研發，在研管線及業務運營方面達到 以下里程碑及進展： REC603－重組九價HPV疫苗 九價HPV疫苗可預防約90%的宮頸癌及90%的肛門及生殖器疣，被廣泛認為是針 對HPV的最有效疫苗。目前，尚無國產九價HPV疫苗獲批在中國銷售。 我們正在進行REC603中國III期臨床試驗，正在按照臨床方案開展定期隨訪工 作。我們正在進行第36個月的訪視觀察。我們將採取病理學終點進行期中分析， 滿足條件後預期將在 ...

江蘇瑞科生物技術股份有限公司 Jiangsu Recbio Technology Co., Ltd. ANNUAL REPORT 2023 年報 江蘇瑞科生物技術股份有限公司 Jiangsu Recbio Technology Co., Ltd. ( a joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） Stock Code 股份代號 : 2179 2023 ANNUAL REPORT 年 報 Contents 目錄 2 Corporate Information 公司資料 5 Chairman's Statement 主席致辭 7 Financial Highlights 財務摘要 8 Management Discussion and Analysis 管理層討論與分析 35 Biographies of our Directors, Supervisors and Senior Management 董事、監事及高級管理層履歷 5 ...

Financial Performance - The company reported total other income and gains of RMB 100,555 thousand for the year ended December 31, 2023, a decrease of 32% from RMB 147,993 thousand in 2022[6]. - The pre-tax loss for the year was RMB 572,443 thousand, an improvement from a loss of RMB 735,996 thousand in 2022, representing a reduction of approximately 22%[8]. - The company incurred a net loss of RMB 572,443 thousand for the year, compared to a net loss of RMB 735,996 thousand in the previous year[8]. - Basic and diluted loss per share was RMB 1.19 for 2023, compared to RMB 1.52 for 2022, indicating a 22% improvement[8]. - The company reported a total comprehensive loss of RMB 570,022 thousand for the year, compared to a loss of RMB 735,996 thousand in the previous year, showing an improvement of approximately 22.5%[10]. - The total liabilities decreased from RMB 1,653,078 thousand in 2022 to RMB 1,070,944 thousand in 2023, a reduction of approximately 35%[7]. - The total loss attributable to equity holders of the parent company for the year ended December 31, 2023, was RMB 571,957,000, a decrease from RMB 722,703,000 in 2022, reflecting a reduction in overall losses[28]. - The company did not record any revenue during the year, indicating a challenging operational environment[19]. Assets and Liabilities - The total non-current assets increased to RMB 1,056,904 thousand in 2023 from RMB 889,687 thousand in 2022, reflecting a growth of approximately 19%[7]. - Current assets decreased to RMB 1,129,373 thousand in 2023 from RMB 1,419,920 thousand in 2022, a decline of about 20%[7]. - Net assets decreased to RMB 1,070,944 thousand in 2023 from RMB 1,653,078 thousand in 2022, a decline of about 35.2%[11]. - The company’s cash and bank balances amounted to RMB 834,983 thousand as of December 31, 2023, compared to RMB 1,325,150 thousand in 2022, indicating a significant decrease[11]. - Trade payables as of December 31, 2023, amounted to RMB 115,081,000, significantly higher than RMB 62,517,000 in 2022, indicating increased operational liabilities[29]. - Other non-current assets decreased from RMB 215,625,000 in 2022 to RMB 122,240,000 in 2023, reflecting a decline in long-term asset holdings[32]. - The company’s equity attributable to owners of the parent remained stable at RMB 482,963 thousand, with treasury shares recorded at RMB (54,005) thousand[11]. Research and Development - The company is advancing the clinical development of its recombinant nine-valent HPV vaccine REC603, with ongoing Phase III trials in China[1]. - The company plans to complete preclinical studies for its new RSV vaccine REC625 by 2024[4]. - Research and development costs were RMB 487,847,000 in 2023, down from RMB 716,444,000 in 2022, a reduction of 32%[22]. - The total R&D cost for the year ending December 31, 2023, was RMB 487.8 million, with no R&D costs capitalized during the same period[60]. - The company has a pipeline of over 10 vaccine candidates, including three strategic products: REC603 (a recombinant 9-valent HPV vaccine in Phase III clinical trials), REC610 (a new adjuvanted recombinant herpes zoster vaccine in Phase I), and a new adjuvanted recombinant respiratory syncytial virus vaccine soon entering clinical research[34][36][41]. Market and Product Development - The company is primarily engaged in vaccine research and development in mainland China, with a focus on expanding its market presence[12]. - The company plans to continue its focus on new product development and market expansion strategies in the upcoming fiscal year[12]. - The company is expanding its market presence in Asia, targeting a growth rate of D% in that region over the next fiscal year[111]. - New product development includes the launch of the nine-valent HPV vaccine, which is expected to capture a significant market share[111]. - The company is investing in new technologies, including mRNA-based vaccines, to diversify its product offerings[111]. Governance and Compliance - The company has confirmed compliance with the corporate governance code, with a focus on maintaining high standards to protect shareholder interests[95]. - The company is committed to complying with corporate governance procedures and information disclosure obligations if a new financing plan is initiated[103]. - The company has established a governance structure that separates the roles of the chairman and CEO, although the current chairman also serves as the general manager[95]. Financing and Capital Management - The company raised a net amount of approximately RMB 669,714 thousand from its global offering after exercising the over-allotment option[96]. - The company allocated 47% of the raised funds (RMB 316,633 thousand) for the optimization and commercialization of its HPV vaccine pipeline, including ongoing Phase III clinical trials[97]. - The company has not recommended a final dividend for the fiscal year ending December 31, 2023, consistent with the previous fiscal year[99]. - The company is actively engaging with investors and considering new financing options due to changes in the market and financing environment[102]. Production and Facilities - The company is constructing an HPV vaccine production base in Taizhou, Jiangsu Province, with a designed peak capacity of 20 million doses of nine-valent HPV vaccine per year, currently in the equipment installation phase[62]. - The production capacity for the 9-valent HPV vaccine at the new facility in Taizhou, Jiangsu Province is designed to be 20 million doses per year, currently in equipment installation and debugging phase[35]. - The Taizhou production facility has a total area of approximately 17,000 square meters and has obtained production licenses from Jiangsu Provincial Drug Administration and compliance statements from EU quality authorities, meeting EU GMP standards[35]. Clinical Trials and Safety - The company is conducting a Phase III clinical trial for its HPV vaccine REC603 in China, with a total sample size of 16,050 participants[42]. - REC603 demonstrated a significant increase in neutralizing antibody (NAb) GMT levels against all targeted HPV types during its Phase I trial, indicating strong immunogenicity[42]. - The incidence of adverse events in the REC603 vaccine group was 53.75%, compared to 86.6% in the Gardasil®9 clinical trial, suggesting better safety[42]. - Interim analysis of the Phase I trial for REC610 in the Philippines indicates good safety and tolerability, with no serious adverse events reported[50]. Future Outlook - The company provided an optimistic outlook for the next quarter, projecting revenue growth of B% and an expected user base increase of C million[111]. - The company plans to review the usage plan for unutilized net proceeds and may revise it as necessary to adapt to changing market conditions[98].

R&D and Clinical Trials - The company is focusing on its strategic pipeline and accelerating the R&D of key varieties, particularly the REC603 HPV 9-valent vaccine, which is currently in a phase III efficacy trial[13]. - The phase III trial for REC603 is being conducted in three provinces: Henan, Yunnan, and Shanxi, with significant progress noted at the 18th month visit and ongoing observations at the 24th month[14]. - The design of the phase III clinical trial protocol aligns with the newly enacted Technical Guidelines for the Clinical Trials of Human Papillomavirus Vaccines, indicating a leading sample size and advantages in clinical site selection[14]. - The company aims for an early market launch of REC603 to meet the urgent global demand for the HPV 9-valent vaccine[14]. - REC610, a novel adjuvanted recombinant shingles vaccine, is currently in phase I/III clinical trials, with a vaccination rate of less than 1% in the Chinese market, indicating strong demand for domestically produced alternatives[15]. - ReCOV, a recombinant COVID-19 vaccine, has received emergency use authorization in Mongolia and is undergoing data analysis for a marketing application in China[17]. - The company aims to expedite the commercial application of its products and enhance core competitiveness in the second half of 2023[21]. - The company has developed a vaccine portfolio consisting of 12 candidates, including REC603, a recombinant HPV 9-valent vaccine currently in phase III clinical trials in China[33]. - The HPV vaccine manufacturing facility in Taizhou, Jiangsu province, has a designed capacity of 20 million doses of HPV 9-valent vaccines per year[31]. - The company has established an IPD System to advance the R&D of multiple vaccine candidates simultaneously[28]. - The vaccine pipeline includes a novel adjuvanted recombinant shingles vaccine currently under clinical research[33]. - The phase III clinical trial for REC603 involves a total of 16,050 subjects and includes primary efficacy, immuno-bridging in younger age groups, and immunogenicity comparison with Gardasil®9[43]. - An interim analysis will be conducted based on pathological endpoints, with plans to submit a BLA application to the NMPA in 2025[43]. - ReCOV, a COVID-19 vaccine, is undergoing international multi-centre Phase III trials in Russia and Nepal, and has received emergency use authorization in Mongolia[37]. - REC610, a novel adjuvanted recombinant shingles vaccine, is currently in phase I trials in the Philippines, with its clinical trial application accepted in China[37]. - The company has not encountered any material unexpected accidents or adverse changes related to REC603 since obtaining IND approval in China[43]. - REC603 achieved a favorable safety profile in the phase I clinical trial, with an adverse event rate of 53.75%, significantly lower than the 86.6% reported for Merck's Gardasil 9[48]. - The company is developing next-generation HPV quadrivalent and 9-valent vaccine candidates with a two-shot regimen, potentially offering superior efficacy compared to current three-shot regimens[58]. - The company is also developing REC602, a bivalent HPV vaccine targeting types 6 and 11, with phase I trials completed in late 2022[66]. - REC604a and REC604b are early-stage HPV vaccines formulated with a novel adjuvant, showing a 7.7 times increase in neutralizing antibodies compared to traditional aluminum adjuvants[69]. - The company has completed phase I clinical trials for its recombinant COVID-19 vaccine, ReCOV, in New Zealand and phase II studies in the Philippines and UAE, with positive results for neutralizing antibodies against the Omicron variant[74]. Financial Performance - The company reported a loss before tax of RMB 276,941,000 for the six months ended June 30, 2023, an improvement from a loss of RMB 357,117,000 in the same period of 2022[23]. - The loss attributable to owners of the parent for the period was RMB 272,549,000, compared to RMB 349,686,000 in the previous year[23]. - Total research and development costs for the six months ended June 30, 2023, amounted to RMB 248 million, with no costs capitalized during the same period[105][106]. - Research and development costs decreased by 30% from RMB 354 million for the six months ended June 30, 2022, to RMB 248 million for the same period in 2023[128][129]. - Clinical trial expenses decreased by RMB 74 million from RMB 179 million to RMB 105 million, mainly due to the progress of core product REC603 in phase III clinical trials[130]. - Total staff costs for the six months ended June 30, 2023, amounted to RMB 116 million, an increase of 14.85% from RMB 101 million for the same period in 2022[118][119]. - Other income and gains decreased by 24% from RMB 79 million for the six months ended June 30, 2022, to RMB 60 million for the six months ended June 30, 2023[124][127]. - Selling and distribution expenses increased from RMB 4 million for the six months ended June 30, 2022, to RMB 5 million for the same period in 2023, attributed to commercialization progress[125][128]. - Administrative expenses slightly increased from RMB 77 million for the six months ended June 30, 2022, to RMB 78 million for the same period in 2023[132]. - Financial costs rose from RMB 1 million to RMB 5 million, primarily due to additional debt financing for R&D projects[134]. - Property, plant, and equipment increased from RMB 559 million as of December 31, 2022, to RMB 618 million as of June 30, 2023, due to new machinery purchases and ongoing construction projects[135]. - Cash and bank balances decreased from RMB 1,325 million as of December 31, 2022, to RMB 1,099 million as of June 30, 2023, primarily due to expenditures on R&D services, raw materials, and administrative expenses[146]. - The current ratio decreased from 4.3 as of December 31, 2022, to 4.0 as of June 30, 2023, primarily due to a decrease in cash and cash equivalents[161]. - The gearing ratio increased to 40% as of June 30, 2023, compared to 28% as of December 31, 2022, due to significant loans taken for production and operations[161]. - Capital expenditure rose from RMB 84 million for the six months ended June 30, 2022, to RMB 102 million for the same period in 2023, mainly due to increased procurement of production equipment[165]. - Capital expenditure commitments increased from RMB 69 million as of December 31, 2022, to RMB 102 million as of June 30, 2023, attributed to progress in research and development projects[166]. Intellectual Property and Patents - The company has applied for a total of 15 invention patents for recombinant vaccines, including those against RSV and HSV, and 16 patents for novel adjuvants and their key materials[18]. - As of June 30, 2023, the company had registered 11 invention patents and filed 103 patent applications, including 100 Chinese and 3 PCT applications[115]. - The company has applied for a total of 15 invention patents related to antigens for various vaccine projects, including HSV and SARS-COV-2[115]. - The company has not been involved in any intellectual property infringement proceedings as of June 30, 2023[115]. Market and Competitive Landscape - The HPV vaccine market in China is significantly underserved, with an estimated 233.9 million females aged 9 to 45 unvaccinated by 2025, indicating a potential demand for 701.7 million doses[53]. - The first domestic HPV bivalent vaccine captured 66.7% of the market share in its first year, suggesting a strong potential for domestic HPV 9-valent vaccines to follow a similar trend[57]. - The company believes that the approval of more HPV 9-valent vaccines in China will lead to a larger market share for these products[52]. - The company is optimistic about the sales prospects of REC610 due to the largely untapped market in developing countries[15]. - The company anticipates benefiting from favorable government policies aimed at accelerating the approval process for domestic HPV vaccines[57]. Shareholder Structure - As of June 30, 2023, Taizhou Yuangong Technology holds 62,147,715 Domestic Shares, representing 17.16% of the company's total shares[183]. - Lianyungang Ruibaitai Medical Technology Partnership owns 8,076,923 Domestic Shares, accounting for 1.67% of the company's total shares[184]. - Beijing Junlian Shengyuan Equity Investment holds 7,084,855 Domestic Shares, which is 5.87% of the company's total shares[184]. - Shanghai Chaorui Medical Technology Partnership owns 29,912,024 H Shares, representing 6.19% of the company's total shares[188]. - YU Yue and LIU Hongyan together hold 7,734,298 Domestic Shares and 30,937,192 H Shares, accounting for 8.01% and 9.79% of the company's total shares respectively[188]. - ZHU Linan has an interest in 10,465,255 Domestic Shares and 37,317,145 H Shares, representing 9.89% and 11.80% of the company's total shares respectively[188]. - The company has a significant number of shares held by various substantial shareholders, indicating a diverse ownership structure[183]. - The report highlights the importance of controlled corporations in the ownership structure, with multiple shareholders having interests in these entities[186]. - The overall percentage of interest in the relevant class of shares shows a strong presence of institutional investors[184]. - The data reflects a stable shareholder base, which may contribute to the company's strategic decisions moving forward[187]. - The total number of H Shares held by various entities indicates a significant interest in the company, with multiple stakeholders holding over 4%[194]. - The company continues to attract investment from various funds and management entities, reflecting strong market confidence[194].

Financial Performance - Total revenue for the six months ended June 30, 2023, was RMB 59,929,000, a decrease of 23.7% compared to RMB 78,593,000 for the same period in 2022[7]. - The pre-tax loss for the period was RMB 276,941,000, an improvement of 22.3% from a loss of RMB 357,117,000 in the previous year[9]. - The net loss attributable to equity holders of the parent was RMB 272,549,000, compared to RMB 349,686,000 in the same period last year, reflecting a reduction of 22.1%[9]. - Other income, including government grants related to income, rose to RMB 29,382 thousand in the first half of 2023, compared to RMB 9,163 thousand in the same period of 2022[20]. - Financial costs for the first half of 2023 were RMB 5,380 thousand, significantly higher than RMB 794 thousand in the same period of 2022, indicating a substantial increase in borrowing costs[22]. - The company reported a foreign exchange gain of RMB 30,242 thousand, down from RMB 66,877 thousand in the previous period[18]. - The company did not declare or pay any dividends for the six months ended June 30, 2023, and 2022[27]. - The basic and diluted loss per share for the six months ended June 30, 2023, was RMB 0.57, compared to RMB 0.75 for the same period in 2022, indicating a 24.0% improvement[28]. Assets and Liabilities - Non-current assets totaled RMB 982,659,000 as of June 30, 2023, an increase from RMB 889,687,000 as of December 31, 2022[8]. - Current assets decreased to RMB 1,262,601,000 from RMB 1,419,920,000 in the previous year[8]. - The total equity as of June 30, 2023, was RMB 1,355,273,000, down from RMB 1,653,078,000 at the end of 2022[8]. - Total current liabilities were RMB 316,164 thousand, down from RMB 328,983 thousand, resulting in a net current asset of RMB 946,437 thousand[10]. - The company's total equity decreased to RMB 1,355,273 thousand from RMB 1,653,078 thousand, indicating a decline of about 18%[12]. - Cash and bank balances decreased from RMB 1,325 million as of December 31, 2022, to RMB 1,099 million as of June 30, 2023, mainly due to expenditures on R&D services, raw materials, and administrative costs[69]. - Trade payables as of June 30, 2023, amounted to RMB 68,708 thousand, an increase from RMB 62,517 thousand as of December 31, 2022, representing a 9.4% increase[29]. Research and Development - The company has applied for 15 invention patents related to its vaccine projects based on its protein engineering and mRNA technology platforms[6]. - Research and development costs decreased to RMB 247,822 thousand in the first half of 2023 from RMB 354,469 thousand in the same period of 2022, a reduction of 30.0%[23]. - The total R&D cost for the six months ending June 30, 2023, was RMB 248 million, with no R&D costs capitalized during the same period[54]. - The company has established three advanced technology platforms for adjuvant development, protein engineering, and immuno-evaluation, enabling continuous discovery and development of subunit vaccines[51]. - The company’s R&D team consists of over 100 professionals, most of whom hold master's or doctoral degrees in relevant fields, ensuring a strong foundation for vaccine development[54]. Vaccine Development - The company has a pipeline of 12 vaccine candidates, focusing on high-burden diseases including HPV, COVID-19, and shingles[31]. - The strategic product REC603, a recombinant nine-valent HPV vaccine, is currently in Phase III clinical trials and is expected to submit a BLA application in 2025[32]. - The company has established a production capacity for HPV vaccines in Taizhou, Jiangsu Province, with an initial design capacity of 20 million doses per year[34]. - The recombinant COVID-19 vaccine ReCOV is undergoing international Phase III trials in Russia and Nepal, with a rolling submission for market approval in China[33]. - The company is developing next-generation HPV vaccines with new adjuvants, designed to use a two-dose regimen, potentially offering advantages over current three-dose products[38]. Corporate Governance and Compliance - The board is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[87]. - The company has established a comprehensive risk management and internal control system, with regular assessments conducted to identify potential risks affecting business operations[88]. - The audit committee, consisting of three members, has reviewed the unaudited interim results for the six months ending June 30, 2023, and found them compliant with relevant accounting standards[89]. - The interim financial report for the six months ending June 30, 2023, has been reviewed by Ernst & Young according to the Hong Kong Institute of Certified Public Accountants' standards[89]. Market and Future Outlook - The company aims to maintain sufficient cash and cash equivalents to meet liquidity needs, balancing continuity and flexibility through bank loans and other borrowings[82]. - The proposed issuance of up to 57,955,560 domestic shares is expected to raise no less than HKD 640 million, with approximately 50% allocated to REC610 for IND application, clinical trials, BLA submission, production facility construction, and commercialization[84]. - The company has entered into a strategic partnership with a leading biotech firm to enhance its product pipeline[99]. - A recent acquisition of a smaller competitor is expected to add $200 million in annual revenue[98]. - The company has set a future revenue guidance of $2 billion for the next fiscal year, indicating a projected growth rate of 20%[99].

Financial Performance - Jiangsu Recbio Technology Co., Ltd. reported a total revenue of RMB 500 million for the fiscal year 2022, representing a year-over-year increase of 25%[4]. - The company achieved a net profit of RMB 100 million in 2022, which is a 15% increase compared to the previous year[4]. - For 2023, Jiangsu Recbio has provided a revenue guidance of RMB 600 million, reflecting an expected growth of 20%[4]. - The company reported a net profit margin of 20% for 2022, reflecting strong operational performance and cost management[193]. - Jiangsu Recbio's total assets increased to CNY 1.2 billion, marking a 10% growth from the previous year, indicating a solid financial position[194]. User Growth and Market Expansion - User data indicates that the company has expanded its customer base by 30%, reaching a total of 1 million active users by the end of 2022[4]. - Jiangsu Recbio plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2024[4]. - The company is planning to expand its market presence internationally, with a goal to enter at least three new countries by the end of 2023[194]. Research and Development - The company has allocated RMB 50 million for research and development in 2023, focusing on innovative vaccine technologies[4]. - The company is actively developing new products, with three new vaccine candidates expected to enter clinical trials in 2023[4]. - The company has developed a vaccine portfolio consisting of 12 candidates, strategically targeting five of the ten diseases with the highest burden according to the WHO's 2019 Global Burden of Diseases[20][21]. - The company has established an IPD System to advance the R&D of multiple vaccine candidates simultaneously[20][21]. - The company aims to enhance its corporate and business strategies under the guidance of its non-executive directors[162]. Clinical Trials and Product Development - The recombinant HPV 9-valent vaccine candidate REC603 is currently in phase III clinical trials in China[25][26]. - The company launched clinical research for its recombinant shingles vaccine, REC610, in the Philippines, indicating expansion in its product pipeline[14]. - The ReCOV vaccine is undergoing international multicenter Phase III trials in Russia and Nepal, with additional Phase I/II trials in China[32]. - The company has advanced clinical trials for its vaccine candidates since December 31, 2022, with no material adverse effects on business operations expected[106]. Operational Efficiency and Strategies - The company has implemented new operational strategies aimed at improving production efficiency by 15% in the upcoming year[4]. - Jiangsu Recbio has implemented new strategies to improve operational efficiency, targeting a 15% reduction in production costs by optimizing supply chain management[194]. - The company has established a robust quality management system to ensure product excellence and compliance with industry standards[199]. Corporate Governance and Management - The company has appointed new executives to strengthen its commercialization capabilities, including a Chief Quality Officer and a Chief Business Officer[14]. - Jiangsu Recbio Technology Co., Ltd. reported significant advancements in its management team, with key appointments including Chen Qingqing as CFO and vice general manager since May 9, 2021[199]. - The management team includes experienced professionals with backgrounds in major companies, enhancing the company's operational capabilities[199]. - The company has established a strong governance framework with independent directors responsible for providing unbiased judgment[173]. Strategic Acquisitions and Partnerships - Jiangsu Recbio is considering strategic acquisitions to enhance its product portfolio and market reach, with potential targets identified in the biotech sector[4]. - The company has initiated discussions for potential mergers and acquisitions to enhance its product portfolio and market reach, aiming for completion by Q4 2023[194]. - The company has established strategic partnerships with leading research institutions to enhance its technological capabilities and accelerate product development[194]. Sustainability and Social Responsibility - Jiangsu Recbio's board of directors has emphasized a commitment to sustainable practices, aiming for a 20% reduction in carbon emissions by 2025[4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Jiangsu Recbio Technology Co., Ltd. 江蘇瑞科生物技術股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2179） 截至2022年12月31日止年度的全年業績公告 及 變更募集資金用途 董事會欣然公佈本集團截至2022年12月31日止年度經審核簡明綜合業績，連同截 至2021年12月31日止年度之經審核比較數字。 業務摘要 於2022年及截至本公告日期，我們在諸多方面取得重大進展： 進一步推動臨床階段的創新疫苗開發 REC603－重組HPV九價疫苗 九價HPV疫苗可預防約90%的宮頸癌及90%的肛門及生殖器疣，被廣泛認為是針 對HPV的最有效疫苗。目前，尚無國產九價HPV疫苗獲批在中國銷售。 • 我們正在進行REC603中國III期臨床試驗。該試驗由主效力試驗、小年齡組 免疫橋接試驗、與Gardasil®9免疫原性比較試驗三部分組成，採用多中心、 隨 ...